Survival outcomes of patients with gastric cancer after open surgery at K Hospital from 2019 to 2023
Main Article Content
Abstract
Gastric cancer is a malignant disease with high mortality, and postoperative survival depends on several prognostic factors, with open surgery still playing an important role in clinical practice. A retrospective study was conducted on 962 patients who underwent open surgery at K Hospital from 2019 to 2023 to evaluate survival outcomes and associated factors. The overall survival rates at 1, 2, 3, and 5 years were 88.1%, 83.2%, 80.2%, and 75.2%, respectively; the 5-year disease-free survival rate was 76.0% in patients who underwent curative resection. Multivariable analysis identified advanced disease stage, age ≥ 60 years old, and postoperative complications as independent prognostic factors associated with reduced overall survival, whereas adherence to adjuvant therapy was independently associated with improved survival. The study clarifies prognostic characteristics of gastric cancer patients after open surgery at K Hospital.
Article Details
Keywords
Gastric cancer, open surgery, overall survival. disease-free survival
References
2. Jeong SA, Yook JH, Yoo MW, et al. Analysis of risk factors affecting long-term survival in elderly patients with advanced gastric cancer. Aging Clin Exp Res. 2023; 35(10): 2211-2218. doi:10.1007/s40520-023-02495-8.
3. Trần Tuấn Anh, Phạm Anh Vũ, Lê Lộc, và cs. Đánh giá kết quả phẫu thuật nội soi cắt toàn bộ dạ dày kèm nạo vét hạch điều trị ung thư dạ dày. Tạp chí Y Dược Huế - Trường Đại học Y - Dược, Đại học Huế. 2023;5:58-66.
4. Chon HJ, Hyung WJ, Kim C, et al. Differentiostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Ann Surg. Published online 2017: 265(5), 946-953.
5. Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014; 21(9): 3008-3014. doi:10.1245/s10434-014-3664-z.
6. Zhao F, Yang D, Lan Y, et al. Different trends of gastric cancer in China, Japan, Republic of Korea and United States of America. iScience. 2024; 27(6): 110074. doi:10.1016/j.isci.2024.110074
7. Obana A, Iwasaki K, Suwa T. Impact of postoperative complications on gastric cancer survival. Surgery. 2025; 178: 108873. doi:10.1016/j.surg.2024.09.031.
8. Kim HH. KLASS (Korean Laparoendoscopic Gastrointestinal Surgery Study Group) trials: a 20-year great journey in advancing surgical clinical research for gastric cancer. Ann Surg Treat Res. 2025; 108(1): 1-11. doi:10.4174/astr.2025.108.1.1.
9. Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer. 2018; 21(1): 144-154. doi:10.1007/s10120-017-0716-7.
10. Kim DW, Kwon OK, Yoo MW, et al. Actual compliance to adjuvant chemotherapy in gastric cancer. Ann Surg Treat Res. 2019; 96(4): 185-190. doi:10.4174/astr.2019.96.4.185.
11. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(12): 1389-1396. doi:10.1016/S1470-2045(14)70473-5.